The Chemistry of Immune Stimulants: How Targeted Delivery Creates Anti- Tumor Immunity

Time: 12:00 pm
day: Conference Day One


  • Examine how Immune-Stimulating Antibody Conjugates (ISACs) harness the mechanisms of the innate immune response and lead to prolonged adaptive immune responses, effectively “teaching” the immune system to recognize and eliminate cancer orphan cells
  • Present clinical data with first generation payloads and how those learnings inform design of next generation payloads
  • Preliminary look at Bolt’s proprietary STING-agonist ISAC, which demonstrates low activity in a cytokine release syndrome safety model, suggesting the potential for improved tolerability and safety advantages over other STING ISACs